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. Immunohistochemical analysis of phosphorylated ERK-5 in human breast and ovarian carcinoma using a semiquantitative scoring system. Staining was performed using Santa Cruz anti phospho ERK5 using TARP arrays of human breast and ovarian carcinomas. Phospho-Erk5 staining was blindly analyzed and scored. Staining intensity is indicated using a semiquantitaive method (<5% = 0, 5%-30% =+1, >30% = +2). The numbers of breast or ovarian samples identified in each group are indicated in parenthesis. Representative images from each staining group are shown side-by-side with respective H&E stained samples.
These results indicated that distinct populations of breast carcinoma expressing activated Erk5 or not existed among clinical breast cancer samples. To determine if well established breast cancer cell lines also displayed difference in activation of the MEK5-Erk5 pathways we again used phospho-Erk5 measurements this time with Western blot analysis of a number of human breast carcinoma cell lines (Figure 2) . In addition to MCF-7 cells, both T47D and ZR-75 cells are model of ER-positive breast carcinoma. SKBR3, MDA-MB-231 cells are well established ER-negative breast cancer models. MDA-MB-361 is utilized as a model of Her2/neu positive breast cancer (153-154). Variants of MDA-MB-361 exists and here we use MDA-MB-361(-) cells that are ERnegative. Using Western blot analysis against ERalpha, total Erk5 or phospho-Erk5 we can observe a clear enhanced activation of Erk5 (as measured by phospho-ERk5 levels) in SKBR3, MDA-MB-231 and MDA-MB-361 cells. Interestingly this activation of Erk5 is inversely correlated with ER expression. Lack of or loss of ER-alpha is indicative of a poor prognosis in breast cancer patients. Additionally the ER-negative cell lines used here exhibit aggressive in vivo growth, hormone-independence and enhanced apoptotic resistance. Our results suggest that phospho-ERK5 may be associated with a more aggressive phenotype.
P -Erk5 P -Erk5
Erk5 1 2 3 4 5 6 . Implicate apoptotic suppression as a mechanism for MEK5-mediated survival and drugresistance (Months 12-24). We next wished to establish a model system to allow us to examine the effects of MEK5-Erk5 signaling on breast cancer progression and tumor growth. To investigate the role for direct activation of MEK5 in the regulation of breast cancer cell phenotype, MCF-7 cells (our N variant (SENSITIVE) from above) were used establish a stable constitutively active MEK5 (CA-MEK5) overexpressing cell line. The use of a CA-MEK5 allows activation of the downstream Erk5 in the absence of any growth factor or survival signal. MCF-7 cells were transfected and stable clones were selected with empty vector (MCF7-VEC) or CA-MEK5 (MCF7-CA-MEK5) ( Figure 3A) . Using these stables cell systems we next set out to determine if loss of clonogenic survival induced by TNF, tamoxifen or the pure antiestrogen fulvestrant (ICI 182,780), was affected by overexpression constitutive active MEK5(CA-MEK5). Using a clonogenicity assay (126,127), we demonstrate that expression of CA-MEK5 in a sensitive cell type (MCF-7) can shift the cell survival/death signaling balance leading to a resistant phenotype (Figure 3B ). Using a SCID model of in vivo tumorigenesis we demonstrate that MEK5 expressing cells possess an early tumor onset and greater tumor growth than VEC cells (Figure 4A) . Of significant interest was the observation that the MEK5 cells were capable of tumor formation in the absence of exogenous estrogen while the ERpositive VEC parent MCF-7 cells were unable to form tumors without estrogen as far out as 50 days ( Figure  4B) , demonstrating MEK5's role in progression to a more malignant hormone-independent phenotype. Consistent with this data was the observation that MEK5 cells will continue to proliferate in the absence of estrogen in vitro as well (not shown). The ability of MEK5 to lead to both an anti-estrogen resistant phenotype in vitro and a hormone-independent phenotype in vivo in many ways parallels what is observed in advanced/recurrent ER+ breast carcinoma's progression to therapeutic resistance. 
Aim 2: To characterize differences in protein expression between MCF-7N (APOP-Sensitive), MCF-7M (APOP-Resistant) and ZR-75-30 breast carcinoma cells and identify anti-apoptotic proteins, such as
Survivin, within MEK5-expressing cell lines. Preliminary Data: Using the newly installed two-dimensional gel electrophoresis system, we have developed and optimized working protocols for i) preparation of protein homogenates from cultured breast carcinoma cells; ii) isoelectric focusing of the protein homogenates in an immobilized pH-gradient gel for the first dimension separation, iii) SDS-PAGE second dimension electrophoresis, and iv) gel imaging (see Figure 5 for example 2D gels). Work is underway to identify protein spots that can yield meaningful information on Image Analysis: Coomassie-stained gels were scanned with a Gel Doc-XR image system (Bio-Rad) using PDQuest software (Bio-Rad) and the proteins of interest were marked for excision. Image analysis of the 2-gels of the two breast cancer cells ( Figure 2 ) revealed very similar protein expression with more than 2100 spots detected on each gel. For preliminary examination, the spots which appear to have sufficient amounts of proteins for LC/MS analysis were excised. Of the 153 spots excised, C2, C5, C7, C11, D9, E11, F2 and H8 were found only in MCF-7Mek5 cells and D4, F7, F8, G1, G3 and G4 were detected only in the MCF-7N cell line. A complete list of excised gel spots is given in Table 1 .
Table 1. List of Excised Gel Spots for MCF-7NvU and MCF-7Mek5
Some other spots appearing different in the two breast cancer cell lines were of low concentrations and were barely detectable by coomassie staining. At the present expression level these spots could not be identified by LC/MS, and it will be necessary to run preparative gels on which more proteins can be loaded. Some of the identified spots are listed in Table 2 (for the MCF-7N cells) and Table 3 (MCF-7MEK5 cells) below. The mass spectrometric identification of all excised gel spots is being carried out using the linear trap tandem mass spectrometer at Children's Hospital in New Orleans.
Most of the identified proteins are the same in the two breast cancer cell lines. For example, B01, B02, D02, E04, E05, F04 spots from MCF-7N are identical to B03, B04, D01, E02, E06, F01, F03 spots from MCF-7Mek5, respectively. Two differing spots have been identified. In the drug sensitive MCF-7N cell line, gel spots E03 and F09 ( Table 2 ) represent different proteins than the corresponding E01 and F06 spots (Table 3 ) from the drug resistant MCF-7Mek5 cell line, respectively. Further experiments are underway to confirm the preliminary findings and to gain insight into the mechanism of drug resistance at the proteomic level. Plan to Purchase an HPLC-Tandem Mass Spectrometer Dr. Wang has secured approximately $200,000 in external funds toward purchasing an HPLC-MS/MS system for dedicated proteomic analysis. Because the instrument costs over $340,000, he is seeking to rebudget most of the year two carryover fund of the DoD BC grant and some of the year three funds for the instrument purchase. Upon approval, Dr. Wang will be able to acquire a complete mass spectrometry system equipped with a two dimensional HPLC for proteomic characterization. The availability of a proteomic mass spectrometer will significantly increase Dr. Wang's productivity on the breast cancer research project and will serve as an important analytical platform for Xavier faculty to conduct cancer-related research.
Aim 3: In this task we will use RNA interference strategies to validate a role for the Erk5 pathway in downstream gene expression and in suppression of chemotherapeutic drug-induced apoptosis. Our preliminary analysis revealed survivin expression was increased in drug-resistance and MEK5 expressing breast carcinoma cells. Subsequently we will characterize the role of these downstream targets such as Survivin, in suppression of apoptosis and drug-resistance.
Aim 3: (a) Optimize pSUPER base RNA interference (RNAi) suppression of ERK5 expression in breast carcinoma cells (Month 15-18).

Aim 3: (b) Confirm a role for Erk5 signaling in MCF-7N-CA-MEK5, and MCF-7M-(RESIST) cell survival using pSUPER-Erk5-RNAi. (Months 18-28).
We next sought to confirm a role for Erk5 signaling in the observed phenotype of MEk5 overexpressing MCF-7 cells. RNA interference (RNAi) is a novel method which through either transient transfection of siRNA or through the use of Pol III driven shRNA expression constructs stably ablates/suppresses expression of specific genes. In our lab, we have used siRNA and shRNA-expression constructs to selectively ablate/suppress target genes. In Figure 6 we demonstrate the use of shRNA expression constructs to generate MCF7-MEK5 cells stably targeting Erk5. Here we show that MCF7-MEK5 cells stably expressing Erk5-shRNA demonstrate a downregulation of Erk5 mRNA (Fig 6A) and protein levels (Fig 6B) as compared to empty-shRNA vectors. The ability of MEK5 expression to enhance tumor formation in immunocompromised mice is suppressed by RNAi-mediated ablation of Erk5 expression ( Figure 5C ). While focusing effort on the RNAi strategies for ERK5 knock-down we have been exploring the mechanisms and targets of Surivin regulation by MEK5-Erk5. Regulation of biological responses to MAPK signaling involves stimulation of transcription factor mediated gene expression. The ability of MEK5 to mediate cell survival may in part occur through activation of transcriptional regulation of survival gene expression. We and others have previously shown an important role for NF-κB activation in the determination of cell survival decisions (21, 25) . Using MCF-7 breast carcinoma cells, we demonstrate above that transfection of CA-MEK5 slightly increasing basal activation in the absence of stimuli as well as potentiates the ability of TNF and PMA to induce NF-κB activity (Figure 7B) . We have confirmed that stable MCF-7-MEK5 cells exhibit a higher basal and TNF-inducible NF-kB luciferase activity as well (not shown). A number of signaling pathways converge at different steps of the NF-κB cascade to stimulate activity. While MEK5 may directly activate the signaling cascade (IKK-IκB-NFκB), potentiation of TNF induced NF-κB activity suggests that MEK5 may coordinately integrate with TNF to enhance NF-κB, resulting in a shift from death receptor signaling towards one of survival. Additionally, STAT3 is critical in regulation of cytokine and growth factor mediated cell survival and its constitutive activation in certain cancers has been demonstrated to suppress apoptosis. Along with NF-κB, STAT3 has also been demonstrated to be targeted by MAPK mediated signaling. Using a similar reporter gene assay for STAT3-mediated transcription we show that CA-MEK alone is capable of potently stimulating STAT3 activation ( Figure 7A ). T To investigate the mechanism by which MEk5 signaling may increase NF-kB activity we examined basal expression of NFκB-p50, NFκB-p65 and IκB-α in MCF-7-VEC versus MCF-7-MEK5 cells. Western blot analysis revealed a higher basal expression of p65 in the MCF-7MEk5 cells similarly basal levels of IkB-α were lower in MCF-7-MEK5 cells. This suggested that MEK5 may function by activating IKK-IkB-p65 pathways leading to NF-kB transcription activation. These results do not rule out the possibility that MEk5 may have direct effects on P65 or IkB expression ( Figure 8A) . gene expression profiling (Affymetrix analysis not shown) of MCF-7-CA-MEK5 cells versus MCF-7-VEC cells revealed increased expression of the key anti-apoptotic gene Survivin. The results suggest that the suppression of cell death by MEK5 may in part occur through upregulation of Survivin. Western blot analysis confirmed a higher expression of Survivin in MCF-7-MEK5 cells (Figure 8A) . To determine if the effects of MEK5 on Survivin expression required NF-kB, MCF-7-MEK5 cells were treated with inhibitors of NF-kB, SN50 (128) or Bay11-7082 (21) . RT-PCR analysis revealed that NF-kB inhibition partially suppressed MEK5 induced Survivin expression ( Figure 8B) . This was further confirmed by examining the full length Survivin-promoter linked to luciferase(129-132) ( Figure 8C ). The data from above suggests that higher levels of Erk5 activation are observed in ER-negative breast cancer cell lines. Additionally our data in the ER-positive MCF-7 line suggests that overexpression of CA-MEK5 drives these cells to an ER-independent phenotype. We have focused on ER signaling as a target regulated by MEK5-Erk5 while continuing our proteomic studies to identify novel markers of drug resistance. We hypothesized that at some level the estrogen receptor pathways are affected by or by-pass MEK5-Erk5 signaling. To determine the effects of MEK5 on ER signaling, an ERE-luciferase reporter assay was used in both transient ( Figure 9A) To determine if activation of the MEK5-Erk5-Pathways affects ER expression levels we examined by PCR the expression of ERalpha in The MCF7-VEC, MCF7-MEK5-(shRNA-empty) and MCF7-MEK5-Erk5-shRNA cells (Figure 10) . These data show that in the MEK5 overexpressing cells, ERalpha is downregulated at the mRNA and protein levels. Blockade of the MEK5-Erk5 pathways by shRNA-Erk5 restores ERalpha expression at both the protein (Figure 10A ) and mRNA levels (Figure 10B ). 
Collaboration between Dr. Wiese at Tulane Cancer Center and Dr. Hill
Dr. Wiese has been in close contact with Dr. Hill since the start of this project through phone, email or meetings. While the project was designed to take place entirely in the Wiese lab, Dr. Hill contimues to provide input on experimental design and data interpretation. The main contribution of Dr. Hill to this project has been discussions relating to the use of microarray technology to identify specific genes or classes of genes that may be related to the observed mixture effects (see Y2 progress of Aim 2 below). Dr. Hill has also provided insight regarding the management of the overall training program (see tasks 2 and 3 below).
Preliminary and Y1 results summary
The series of pesticides included in this study included isomers and metabolites of DDT and methoxychlor. Each are known to have weak estrogen, androgen and/or progesterone activity. A series of MCF-7 proliferation studies were conducted to identify novel interaction effects of binary mixtures of these compounds. The initial studies were designed to include one pesticide at the lowest observed effect level (LOEL) and the other at the highest dose possible (10-5 M) . Experiments were also conducted to determine if mixing the pesticide (high dose) with sub-optimal concentrations of estradiol-17β (E2) enhanced estrogen induced proliferation. This series of experiments did not identify mixture combinations with more than the additive cell proliferation activity expected from the compounds alone at the same concentrations. These same mixtures were examined in the MVLN estrogen responsive reporter gene assay where similar additive effects were also observed. See Y1 progress report for more information. At this point, Dr. Wiese decided to examine mixtures that contained one of the organochlorine pesticides along with one of three organophosphate pesticides. We have observed a positive sensitizing or potentiation effect of organophosphate pesticides on the weak estrogen dependant proliferation activity of organochlorine pesticides (increased potency). This action can be eliminated by antiestrogen and is likely estrogen receptor (ER) dependant. The observation that this sensitizing effect was not observed in the reporter gene system suggests that the mechanisms involved are more complex than a simple stimulation of classical ER transactivation activity. Finally, the observation of this sensitizing effect suggests a hypothesis that exposure to low levels of weakly estrogenic pesticides in combination with an organophosphate pesticide might result in more breast cancer cell proliferation than would be expected by the organochlorine alone. The organophosphate compounds in this study are known to have antiandrogen activity. Considering that androgen agonists are known to inhibit estrogen regulated processes in some cells, it is reasonable that treatment with antiandrogens may relieve such suppression, resulting in a relative increase in organochlorine induced estrogen activity. The organochlorine compounds in the study are considered persistent contaminants with long elimination half lives. Thus, chronic exposure to low concentrations may have more estrogenic activity than would be expected if cells are sensitized or stimulated by periodic exposure to organophosphate pesticides. Contamination from older pesticides that are no longer used might be more significant if one is exposed to current use pesticides. See Y1 progress report for more information.
Year 2 activities related to Aim 1 included completing the matrix of pesticide combinations in the proliferation and MVLN reporter gene assays. Mixture combinations that produced the most dramatic sensitization effect in the breast cancer cells were selected for microarray analysis in Aim 2. These are: Parathion and opDDT, Fenitrothion and opDDT, and HPTE and opDDT.
Aim 2: Conduct cDNA microarrays to define a set of genes that are coordinately or differentially regulated by treatment with environmental hormones. Preparations from cells grown and exposed to mixtures of hormone active pesticides in the Wiese Lab will be evaluated for differential expression of genes in the Tulane Center for Gene Therapy. (a). Identify target genes related to breast cancer cell proliferation from literature searches that will be used in gene array studies (Months 1−12). (b) Prepare cells for gene array analysis after exposure to mixtures of pesticides. (Months 9−24). (c) Run gene array analysis on cell preparations and analyze data (Months 12−36).
Year Two Progress
In Year 1, we decided to use focused microarrays such as SuperArray rather than the Affymetrix arrays available in the Tulane Cancer Center. This will reduce the cost of the microarray experiments and allow us to focus more on nuclear receptor mechanisms and cancer related genes. In Y2, Dr. Wiese and Mr. Segar in the Wiese lab did background research on the SuperArray system and ordered some arrays to test at Katrina disrupted activities. Plans are to set up the SuperArray system in the lab once the lab is fully operational and we can repeat the novel mixture results identified in Y1 and refined in pre-Katrina Y2.
Aim 3: Confirm the expression pattern of genes identified by microarray through analysis of gene products (mRNA or protein). (a) Select 6−10 genes that have been shown by differential display to have novel expression patterns as a result of pesticide mixture treatment (Months 14−36). (b) Obtain probes for Northern blot analysis of selected genes (Months 14−36). (c) Perform Northern blots to confirm expression observed in micro array studies (Months 24−48). (d) Obtain antibodies for Western blot analysis of selected genes (Months 14−36).
(e) Perform Western blots to confirm expression observed in micro array studies (Months 24−48).
Year One Progress
No progress on this aim in year 2.
Deliverables/measurable outcomes:
Drs. Wang and Wiese will prepare or oversee the following:
Semiannual reports will be submitted to the PI.
Year Two Progress These reports were submitted and have bee used to make this progress report. 24, 36, 48 ).
Students involved in the research will present a poster at the annual research workshop (Months 12,
Year Two Progress
In Y2, one Xavier undergraduate student was involved in research activities supporting the breast cancer project in the Wiese lab. Ashley White, a chemistry major and Xavier RISE scholar joined the Wiese lab in May 2004 and worked on this project through project Y1 and into Y2. Ashley has very good lab skills, was well trained in the lab and after graduation, she planned to continue working on this project for the next few yesrs while she was in pharmacy school at Xavier (started August 2005). However, Ashley did not return to Xavier after Huricaine Katrina. Another student will be selected to work on this project in the second half of 2006, after the lab is fully operational and after Xavier students are caught up with 2005-2006 school year courses running through the summer of 2006.
Dr. Wang will identify an undergraduate student to work on his project in the second half of 2006 or in early 2007. The method development required for his project in Y1 was not appropriate for student training. At the same time, the lab recovery process undertaking in first half of 2006 is also difficult for student traiing because the students is not able to generate a product.
Both Dr. Wang and Wiese feel that the most effective student training only occurs when the full time staff members of the lab have sufficient expertise in the methodologies used in the lab. Thus, Y1 in both labs was dedicated to building expertise so that students in Y2 and beyond will have sold faculty and staff mentors from which to learn lab skills.
Drs. Wang and Wiese also have experience mentoring Xavier students in the MARC and RISE programs at Xavier. Once these programs are reestablished on campus in late 2006, both of Drs. Wang and Wiese will be bringing in at least one additional student into their labs.
One competitive grant application will be submitted by the end of the funding period.
Year Two Progress Submission of a major equipment proposal to DoD for the acquisition of a tandem mass spectrometer.
In an effort to build up Xavier's capability to conduct independent proteomic research, Dr. Wang submitted a major equipment proposal to DoD's to the Army Research Office for consideration under ARO Broad Agency Announcement W911NF-05-R-0001 in 2004. The proposal was entitled "High Performance Liquid Chromatography-Tandem Mass Spectrometry for Enhancement of Teaching and Research at Xavier University" and asked for $196,392 for the purchase of an HPLC-MS/MS system. One of the major justifications for the proposal is the ongoing breast cancer research project for which the availability of such an instrument is essential. This proposal was not funded.
After returning to Xavier in January 2006 from the Katrina Evacuation, Drs. Wiese and Wang identified funds from 3 grants that could be rebudgeted to purchase the core components of the HPLC and Mass Spectrometry equipment requested in the above proposal. After, optaining approval from funding agencies, rebudgeting was done and the equipment was purchased in the first quarter of 2006. Thus, the core instrumentation equipment required to do proteomic analysis will be set up in Dr. Wangs lab in 2006.
Submission of a P20 planning grant to the NCI
A P20 planning grant was developed and submitted to the NCI in Y1. More details are provided in the Y1 progress report of Task 3 below.
4. Papers will be submitted to peer reviewed journals through the funding period.
Year Two Progress
No manuscripts were submitted in Y2.
Training deliverables:
The Tulane Cancer Center in conjunction with the Section of Hematology and Medical Oncology and The Cell Signaling group will be directly involved in providing breast cancer research training for Xavier Investigators.
Year Two Progress
The support provided from the TCC to each project is described within the progress reports of each project above. In addition, TCC support for the program as a whole is detailed in Task 3 below.
Toward the end of the project period, Drs. Wang and Wiese will be Co−PIs in writing an R01 grant in collaboration with
Drs. Burow and Hill.
Year Two Progress
No R01 collaborative grants are in preparation at this time. We expect that during Y3, the planning for at least one collaborative grant will be started.
Task 2 Assist two Xavier junior faculty to become more competitive in breast cancer research a. Identify two Junior Faculty with interest in breast cancer research (Month 1).
Year Two Progress
In 
b. Establish participation of the selected Junior Faculty in Tulane Cancer Center seminars and the weekly signal transduction workshop focused on breast and prostate cancer (Month 2).
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Year Two Progress A regular group of XU faculty involved in the DOD Breast and Prostate cancer projects are attending the TCC and LSU CC seminars held most Thursdays at noon. Attendance has reduced after the Katrina evacuation since faculty are involved in additional responsibilities and lab recovery efforts. The LCRC signal transduction workshops have not yet started meeting. Dr. Wiese has discussed this situation with Dr. Hill who is in the process or reorganizing these workshops after the Katrina recovery. Xavier faculty involved in the DOD BC and PC programs have meet and decided to form a regular work in progress seminar meeting at Xavier starting in Fall 2006.
c. Determine Tulane Cancer Center mentors for the Junior Faculty and submit a two−page mini proposal for review of the PI and alternate PI (Month 6).
Year Two Progress
Dr. Wolfgang has been matched with Dr. Miller and they have developed the following idea for a miniproposal:
The protein p23 is up regulated in cancer cells. It is a co-chaperone of heat shock protein 90 (Hsp90). Hsp90 is involved in the maturation of signaling proteins such as estrogen receptor. Activation of the estrogen receptor is important in the formation and progression of breast cancer. p23 stimulates Hsp90 to release its substrates. Dr. Miller has mouse fibroblast cells in which he has knocked-out the p23 gene. He also has stably transfected some of those cells with the p23 gene. This provides two cell lines with the only difference being the expression of p23. We will conduct experiments with various drugs such as geldanamycin, novobiocin, and herbimycin. The molecule 17-allylaminogeldanamycin is already in clinical trials. These drugs function to inhibit Hsp90 activity. Normal cells and cancerous cells both have the same amount of Hsp90 but cancer cells have more of the Hsp90 in its active dimmer form. p23 helps keeps keep Hsp90 in the active form. We will be looking for differential toxicity between the cells with p23 and the cells without p23. The goal is to find drugs with toxicity toward the p23 cells.
Initially the work will be done at Tulane. Since I have limited experience with cell culture the work will initially be carried out at Tulane. Currently my Tuesdays are free to go to Tulane. Once I'm comfortable working with the cells I can move the work to Xavier. Dr. Tom Weise has a functioning cell culture incubator and hood. The Chemistry Department also has an incubator and hood that are currently not in use. I currently have one Chemistry senior student working on another project but I have three Biology sophomore students who I would like to get involved with p23 project.
See Appendix 2 and 3 for CVs of Drs. Wolfgang and Miller.
d. Junior Faculty collect preliminary data (Months 7−36).
Year Two Progress
See Task 2 c for current status of the Wolfgang-Miller project.
e. Junior Faculty develop grant proposal (Months 36−48).
Year Two Progress
No Progress in this area in Y1.
Task 3
Establish infrastructure that will create an environment that fosters breast cancer research, in which Xavier faculty will receive substantive training and become more competitive for DoD funding 
Conclusions
In Y1 of this training program, we have established two collaborative breast cancer research projects and have identified faculty that can develop additional projects in Y2. Most importantly, we have built a framework of activities for XU faculty to utilize for interaction with the TCC to develop cancer research initiatives involving Xavier undergraduate and pharmacy students.
Year Two Synergy and Opportunities
In Y2, we plan to build on established interactions with the XU-TU DOD Prostate Cancer program. Examples of the resulting synergy will be the cancer research symposia, group training activities such as attendance to seminars and TCC focal group meetings, research collaborations and perhaps even sharing TCC mentors that support both the breast and prostate training programs. We also expect to start interaction between XU students involved in both cancer training programs, will encourage student training between the two programs and will include student presentations in the symposia. In Y2, we will also explore the potential for interacting with other HBCUs that have DOD cancer grants to develop a program where students from HBCUs doing cancer research spend a summer at another HBCU institution learning techniques and gaining experience.
Year Two Challenges
The top program priority of Y2 is to establish Dr. Wolfgang and an XU Pharmacy clinical faculty with a TCC mentor to develop a project. The challenge in this process is two fold. Finding the right TCC faculty that is not already overloaded with research and academic responsibilities and then finding the time in the heavily loaded schedule of the clinical faculty so they can develop a project. In Y2 we expect to increase the number of XU students working on the cancer projects. Drs. Wang, Wolfgang and Wiese will pick up MARC and RISE students in the summer and fall semester. Dr. Wolfgang presents a summer program at XU for RISE students where they learn basic molecular techniques. Through this process, he will gain good rapport with the RISE students which should result in an easy transition for the students into research projects. We hope to get XU pharmacy students involved in this program through clinical faculty who develop projects. The two primary research projects of this program must continue to develop capacity for their projects. Aim 1: To demonstrate the requirement for and the role of the MEK5 pathway in survival signaling and suppression of apoptosis in MCF-7 breast carcinoma cells (Burow Lab). Aim 2: To characterize differences in protein expression between MCF-7N (APOP-Sensitive), MCF-7M (APOP-Resistant) and ZR-75-30 breast carcinoma cells and identify anti-apoptotic proteins, such as Survivin, within MEK5-expressing cell lines (Wang Lab). Aim 3: In this task we will use RNA interference strategies to validate a role for the Erk5 pathway in downstream gene expression and in suppression of chemotherapeutic drug-induced apoptosis (Burow and Wang Labs).
We have established that expression/activation of the MEK5-Erk5 pathways promoters enhanced tumor growth/formation and progression to hormone-independence of in vivo breast tumors in immunocompromised mice. MEK5 cells were capable of tumor formation in the absence of exogenous estrogen while the ER-positive VEC parent MCF-7 cells were unable to form tumors without estrogen, demonstrating MEK5's role in progression to a more malignant hormone-independent phenotype. The ability of MEK5 to lead to both an anti-estrogen resistant phenotype in vitro and a hormone-independent phenotype in vivo in many ways parallels what is observed in advanced/recurrent ER+ breast carcinoma's progression to therapeutic resistance. We have developed and optimized working protocols for i) preparation of protein homogenates from cultured breast carcinoma cells; ii) isoelectric focusing of the protein homogenates in an immobilized pH-gradient gel for the first dimension separation, iii) SDS-PAGE second dimension electrophoresis, and iv) gel imaging. Work is underway to identify protein spots that can yield meaningful information on differential protein expression (both qualitative and quantitative) between the MCF-MEK5 and MCF-VEC cell lines as well as the development of methods for spot cutting, trypsin digestion, and peptide separation and identification by HPLC-MS/MS. We have further established that shRNA targeting of Erk5 abrogates the ability of MEk5 to enhance tumor growth through the use of RNA interference (RNAi) through either transient transfection of siRNA or through the use of PolII driven RNAi expression constructs to stably ablate/suppress expression of specific genes. The ability of MEK5 expression to enhance tumor formation in immunocompromised mice is suppressed by RNAi-mediated ablation of Erk5 expression. Aim 1: Examine the effects of binary mixtures of estrogen and progestin active environmental compounds on cell proliferation and survival (Wiese Lab). Aim 2: Conduct cDNA microarrays to define a set of genes that are coordinately or differentially regulated by treatment with environmental hormones. Preparations from cells grown and exposed to mixtures of hormone active pesticides in the Wiese Lab will be evaluated for differential expression of genes in the Tulane Center for Gene Therapy (Wiese Lab and LCRC Cores). Aim 3: Confirm the expression pattern of genes identified by microarray through analysis of gene products (mRNA or protein) (Wiese Lab).
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We have observed a positive sensitizing or potentiation effect of organophosphate pesticides on the weak estrogen dependant proliferation activity of organochlorine pesticides (increased potency). The organochlorine compounds in the study are considered persistent contaminants with long elimination half lives. Thus, chronic exposure to low concentrations may have more estrogenic activity than would be expected if cells are sensitized or stimulated by periodic exposure to organophosphate pesticides. Contamination from older pesticides that are no longer used might be more significant if one is also exposed to current use pesticides.
Year 2 activities will include completing the matrix of pesticide combinations in the proliferation and estrogen regulated reporter gene assays to include all combinations of concentrations. In addition, ER binding assays will be used to determine if mixtures have effects on compounds binding to receptor. Mixture combinations that produce the most dramatic sensitization effect in the breast cancer cells will be selected for microarray analysis in Aim 2.
Losses to Projects 1 and 2 from Hurricane Katrina
Storm related events such as wind and floods shut off power to the Wiese and Wang labs at Xavier and the Burow lab at the Tulane Medical Center. While none of these labs were structurally damaged by the storm (no broken windows or flooding), each lab suffered the total loss of refrigerators and freezers. All perishable lab supplies, kits and samples were lost along with many chemicals that are not stable long term at room temperature or higher. Cell cultures in the Wiese and Burow labs were stored in liquid nitrogen cryo tanks. Each set of tanks from both labs was removed to a safe location in September and all are currently being maintained. Thus, this request for support addresses only perishable supplies and kits to support cell culture experiments and 2D gel analysis and does include the purchase or procurement of cell lines.
Budget
General Chemicals, Reagents and Molec Bio Kits $9,000 Tissue Culture Reagents and Supplies $11,000 2D Gel Reagents and Supplies $5,000 Total Budget $25,000
Budget Justification
A sum of $9,000 is requested for General Chemicals, Reagents and Molec Bio Kits to restart this projects research activities in the Wiese, Burow and Wang labs. In the Burow lab, $3,000 is requested for obtaining new MEK5 antibodies as well as Erk5 siRNA. In the Wang Lab, $2,000 is requested to replace protein assay kits and standards as well as buffers, ampholytes and RNAse and DNAse.
In the Wiese lab, $4,000 is requested to replace all steroid and pesticide standards, obtain new recombinant ER kits used in receptor binding assays obtain new luciferase assay reagents used for reporter gene assays.
A sum of $11,000 is requested for Tissues culture Reagents and Supplies required to restart cell culture activities in the Wiese and Burow labs. Funds are requested to purchase fetal bovine sera and dextran coated charcoal treated fetal bovine sera as well as to obtain DMEM media, HBSS and DPBS buffers, trypsin, antibiotic solution, nonessential amino acids, l-glutamine, sodium pyruvate, insulin, etc.
A sum of $5,000 is requested for 2D gel Reagents and Supplies used in the proteomic characterizations done in the Wang lab. Items that must be replaced include: IEF and SDSPAGE standards, Silver Stain kits, IEF ready strips and PAGE gels.
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